1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Uterine Leiomyoma (Uterine Fibroids) Global Clinical Trials Review, H2, 2015

Uterine Leiomyoma (Uterine Fibroids) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Uterine Leiomyoma (Uterine Fibroids) Global Clinical Trials Review, H2, 2015" provides an overview of Uterine Leiomyoma (Uterine Fibroids) clinical trials scenario. This report provides top line data relating to the clinical trials on Uterine Leiomyoma (Uterine Fibroids). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Uterine Leiomyoma (Uterine Fibroids) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Uterine Leiomyoma (Uterine Fibroids) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Uterine Leiomyoma (Uterine Fibroids) 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials 31
Prominent Drugs 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
AbbVie Inc. 33
Clinical Trial Overview of AbbVie Inc. 33
Repros Therapeutics Inc. 34
Clinical Trial Overview of Repros Therapeutics Inc. 34
Neurocrine Biosciences, Inc. 35
Clinical Trial Overview of Neurocrine Biosciences, Inc. 35
PregLem SA (Inactive) 36
Clinical Trial Overview of PregLem SA (Inactive) 36
Bayer AG 37
Clinical Trial Overview of Bayer AG 37
Pfizer Inc. 38
Clinical Trial Overview of Pfizer Inc. 38
Mediterranea Medica S.L. 39
Clinical Trial Overview of Mediterranea Medica S.L. 39
Allergan Plc 40
Clinical Trial Overview of Allergan Plc 40
Novartis AG 41
Clinical Trial Overview of Novartis AG 41
ICON Plc 42
Clinical Trial Overview of ICON Plc 42
Clinical Trial Overview of Top Institutes / Government 43
Eunice Kennedy Shriver National Institute of Child Health and Human Development 43
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 43
University Magna Graecia 44
Clinical Trial Overview of University Magna Graecia 44
CHA University 45
Clinical Trial Overview of CHA University 45
Iran University of Medical Sciences 46
Clinical Trial Overview of Iran University of Medical Sciences 46
University of Mannheim 47
Clinical Trial Overview of University of Mannheim 47
University of Sao Paulo 48
Clinical Trial Overview of University of Sao Paulo 48
American University of Beirut Medical Center 49
Clinical Trial Overview of American University of Beirut Medical Center 49
Babol University of Medical Sciences 50
Clinical Trial Overview of Babol University of Medical Sciences 50
Carmel Medical Center 51
Clinical Trial Overview of Carmel Medical Center 51
Catholic University of the Sacred Heart 52
Clinical Trial Overview of Catholic University of the Sacred Heart 52
Five Key Clinical Profiles 53
Appendix 107
Abbreviations 107
Definitions 107
Research Methodology 108
Secondary Research 108
About GlobalData 109
Contact Us 109
Disclaimer 109
Source 110

List of Tables
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Region, 2015* 7
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, G7 Countries (%), 2015* 15
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, E7 Countries (%), 2015* 18
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Terminated Clinical Trials, 2015* 27
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2015* 33
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Repros Therapeutics Inc., 2015* 34
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Neurocrine Biosciences, Inc., 2015* 35
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by PregLem SA (Inactive), 2015* 36
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2015* 37
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 38
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mediterranea Medica S.L., 2015* 39
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan Plc, 2015* 40
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 41
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by ICON Plc, 2015* 42
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2015* 43
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Magna Graecia, 2015* 44
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by CHA University, 2015* 45
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Iran University of Medical Sciences, 2015* 46
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Mannheim, 2015* 47
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2015* 48
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by American University of Beirut Medical Center, 2015* 49
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Babol University of Medical Sciences, 2015* 50
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Carmel Medical Center, 2015* 51
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials Market, Global, Clinical Trials by Catholic University of the Sacred Heart, 2015* 52

List of Figures
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, G7 Countries (%), 2015* 15
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials, E7 Countries (%), 2015* 18
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 108

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • January 2017
    5 pages
  • Therapy  

  • Netherlands  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Insulin Market and Diabetes Statistics in the US

  • January 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

33 hours ago

Therapy Market

33 hours ago

Related Market Segments :

Therapy
Clinical Trial

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.